Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3557354 | 0.95 | HPGD (0.55) | HPGDLMNAHTTSMN1; SMN2CA1 | |
| SCHEMBL3554342 | 0.90 | LMNA (0.51) | HPGDLMNAAKR1C3SLC16A3KMT2A | |
| SCHEMBL3559039 | 0.89 | AR (0.52) | HPGDLMNACA1CA2AR | |
| SCHEMBL3557393 | 0.88 | HPGD (0.59) | HPGDCA1CA2AKR1C3AR | |
| SCHEMBL3560646 | 0.88 | KDM4E (0.49) | HPGDLMNAHTTSMN1; SMN2CA1 | |
| SCHEMBL3555543 | 0.86 | HPGD (0.50) | HPGDLMNAHTTSMN1; SMN2 | |
| SCHEMBL3555917 | 0.86 | HPGD (0.62) | HPGDLMNAHTTSMN1; SMN2AR | |
| SCHEMBL3552908 | 0.84 | CA1 (0.46) | CA1CA2AKR1C3SLC16A3MEN1 | |
| SCHEMBL3555334 | 0.84 | KAT6A (0.56) | CA1CA2SLC16A3MEN1KMT2A | |
| SCHEMBL3555180 | 0.84 | ALDH1A1 (0.57) | CA1CA2SLC16A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | HPGD 389/4885LMNA 2120/4885HTT 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.